Perspective on Pharmacokinetic Comparability for Biologics Development
- 17 September 2026
- journal article
- perspective
- Published by Wiley in Clinical Pharmacology & Therapeutics
Abstract
Comparability assessment of biologics is essential to support manufacturing changes throughout drug development life cycle. Centering on pharmacokinetic comparability for biologics, this manuscript summarizes current and emerging insights drawing from a webinar hosted by the American Society for Clinical Pharmacology and Therapeutics Life Cycle Management Community. The common theme across industry and regulatory experiences is the use of risk‐based, hierarchical approaches to bridge pre‐ and post‐change products, ranging from foundational analytical comparability to clinical pharmacokinetic comparability studies.Keywords
This publication has 5 references indexed in Scilit:
- Insights into PK ‐Based Bridging for Products Using a Common Autoinjector Platform: A Review of 16 Autoinjectors in 14 Biological License ApplicationsClinical Pharmacology & Therapeutics, 2026
- Patient-centric Comparability Assessment of BiopharmaceuticalsJournal of Pharmaceutical Sciences, 2024
- Pharmacokinetics‐Bridging Between Autoinjectors and Prefilled Syringes for Subcutaneous Injection: Case Examples Revealing a Knowledge GapClinical Pharmacology & Therapeutics, 2024
- A survey of FDA Approved Monoclonal Antibodies and Fc-fusion Proteins for Manufacturing Changes and Comparability AssessmentPharmaceutical Research, 2023
- Risk-Based Comparability Assessment for Monoclonal Antibodies During Drug Development: A Clinical Pharmacology PerspectiveThe AAPS Journal, 2018